According to a study published in JAMA Internal Medicine, outpatient process measures need a fair balance between measures for underuse and overuse of clinical services.
At an attempt to improve quality of healthcare, a number of clinical performance measures have been developed to improve clinician and institutional performance. However, the influence of these measures on changing clinical practice on a large scale have been questioned. A primary question being raised, and which was the objective of the current study in JAMA Internal Medicine, is that a focus on underuse and rewarding physicians to do more would tilt the balance toward overutilization.
The authors of the study, in an attempt to understand the influence of outpatient process measures on underuse and overuse, identified all outpatient and emrgency department (ED) process measures included in major national measure programs till mid-2012. Inpatient measures were excluded from the evaluation, as were outcomes measures, settings other than outpatient or ED, and nonclinical aspects of care. A total of 521 measures of care were included in the study from across 16 measure collections.
A detailed evaluation of these measures showed that nearly 92% (477) targeted underuse while just over 6% (34) targeted overuse. Less than 3% (14) addressed misuse. Of the 16 measure collections, the authors found only 3 that included a good percentage of overuse measures (≥10%) while more than 50% did not include any overuse measures. Underuse measures, the authors write, covered all categories of clinical service, while overuse measures were restricted and addressed either diagnostic imaging or medication prescription.
According to Erika Newton, MD, MPH, one of the study's senior authors, "Our findings suggest that, by focusing almost single-mindedly on identifying and penalizing underuse, current outpatient performance measures may well foster a culture of ‘more is better’─and inadvertently encourage overuse of care." The authors believe their findings highlight the need to anticipate and monitor intended and unintended consequences of measure programs and the need for a fair balance between measureing underuse and overuse of clinical services across the spectrum.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
ICS Use Tied to Fewer Exacerbations in Patients With Bronchiectasis and Elevated Blood Eosinophils
June 6th 2025Inhaled corticosteroid (ICS) use was common among patients with bronchiectasis and was associated with reduced exacerbations and hospitalizations in those with elevated blood eosinophil counts.
Read More
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More